The company has received approval from the Drugs Controller General of India (DCGI) to manufacture and market Semaglutide ...

Sun Pharma receives DCGI approval to launch generic semaglutide injection, Noveltreat, for weight management in India.

Sun Pharmaceutical Industries announced that it has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection.

Sun Pharma receives DCGI approval to launch generic Wegovy semaglutide in India after patent expiry in March 2026. Check ...

India's top drug maker Sun Pharmaceutical Industries has announced today the launch of a generic version of semaglutide, the ...

Besides Sun Pharma, a growing roster of Indian drugmakers is lining up cheaper generic versions of semaglutide ahead of the ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for weight management as an adjunct to a reduced-calorie diet and increased physical activity.

Sun Pharma receives DCGI approval to market generic semaglutide injection for chronic weight management in India. Launch after patent expiry.

DCGI approval to Sun Pharma comes amid an ongoing patent dispute with Novo Nordisk in the Delhi High Court. The case relates ...

Approval clears the regulatory path for a lower-cost GLP-1 weight-loss drug in India, but commercial launch hinges on semaglutide patent expiry.

A recent report estimates that major US carriers could collectively save up to $580 million annually, thanks to the weight loss drugs ...

Sun Pharma has received DCGI approval to launch Noveltreat, a generic semaglutide injection for chronic weight management in India. This GLP-1 receptor agonist will be available after patent expiry, ...